Melanoma & Skin

CTD - Clinical Trials Data

Abbreviations

Primary tumour

Liver

Ovary

Melanoma / Skin

Terms

BRIM-3

VEMR vs daca

L1

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

First author: Paul B. Chapman

CA184024

IPI+DACA vs PLB+DACA

L1

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

First author: Caroline Robert

COMBI-AD

DABR TRAM vs PLB

ADJ

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

First author: G.V. Long

COMBI-d

DABR+TRAM vs DABR+PLB

L1

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

First author: G.V. Long

COMBI-v

DABR+TRAM vs VEMR

L1

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

First author: C. Robert

CheckMate 066

NIVO vs DACA

L1

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

First author: Caroline Robert

CheckMate 067

NIVO+IPI vs NIVO

L1

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

First author: J.D. Wolchok

CheckMate 067

NIVO+IPI vs IPI

L1

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

First author: J.D. Wolchok

CheckMate 067

NIVO vs IPI

L1

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

First author: J.D. Wolchok

CheckMate 204

NIVO+IPIL vs na

L1

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

First author: Hussein A. Tawbi

CheckMate 238

NIVO vs IPIL

ADJ

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

First author: J. Weber

KEYNOTE-006

PEMB q3w vs IPIL q3w

L1

Pembrolizumab versus Ipilimumab in Advanced Melanoma

First author: Caroline Robert

KEYNOTE-054

PEMB vs PLB

ADJ

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

First author: Alexander M.M. Eggermont

METRIC

TRAM vs chemo

L1

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

First author: Keith T. Flaherty

NA

IPIL vs PLB

ADJ

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

First author: A.M.M. Eggermont

NA

VEMR vs NA

L2

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

First author: Jeffrey A. Sosman

RELATIVITY-047

RELA+NIVO vs NIVO

L1

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

First author: Hussein A. Tawbi

coBRIM

VEMR+COBI vs VEMR+PLB

L1

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

First author: James Larkin

Terms

© 2021 - 2024 | MedAgora Consulting srl